Endocyte Company Profile (NASDAQ:ECYT)

About Endocyte (NASDAQ:ECYT)

Endocyte logoEndocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:ECYT
  • CUSIP: 29269A10
  • Web: www.endocyte.com
Capitalization:
  • Market Cap: $220.96 million
  • Outstanding Shares: 42,575,000
Average Prices:
  • 50 Day Moving Avg: $2.94
  • 200 Day Moving Avg: $2.11
  • 52 Week Range: $1.17 - $6.55
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.11
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $70,000.00
  • Price / Sales: 3,156.63
  • Book Value: $2.72 per share
  • Price / Book: 1.91
Profitability:
  • EBITDA: ($40,600,000.00)
  • Net Margins: -61,437.14%
  • Return on Equity: -32.68%
  • Return on Assets: -31.29%
Debt:
  • Current Ratio: 22.81%
  • Quick Ratio: 22.81%
Misc:
  • Average Volume: 2.98 million shs.
  • Beta: 1.62
  • Short Ratio: 2.55
 

Frequently Asked Questions for Endocyte (NASDAQ:ECYT)

What is Endocyte's stock symbol?

Endocyte trades on the NASDAQ under the ticker symbol "ECYT."

How were Endocyte's earnings last quarter?

Endocyte, Inc. (NASDAQ:ECYT) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.03. The firm had revenue of $0.01 million for the quarter. Endocyte had a negative net margin of 61,437.14% and a negative return on equity of 32.68%. During the same period in the prior year, the company posted ($0.25) EPS. View Endocyte's Earnings History.

Where is Endocyte's stock going? Where will Endocyte's stock price be in 2017?

3 brokers have issued twelve-month target prices for Endocyte's stock. Their predictions range from $7.00 to $7.00. On average, they anticipate Endocyte's stock price to reach $7.00 in the next twelve months. View Analyst Ratings for Endocyte.

What are analysts saying about Endocyte stock?

Here are some recent quotes from research analysts about Endocyte stock:

  • 1. According to Zacks Investment Research, "Endocyte reported wider than expected loss in second-quarter 2017. During the quarter, the company stopped enrollment in the phase Ib study evaluating EC1456 for lung cancer as well as stop enrollment of taxane-naive metastatic castration-resistant prostate cancer patients for EC1169. The company now plans to focus on its most promising programs like CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform, and its pipeline candidate EC2629. However, with no approved product in its portfolio at the moment, Endocyte has to depend heavily on its partners for top-line growth. Moreover, shares of the company have underperformed the industry year to date." (8/14/2017)
  • 2. Cowen and Company analysts commented, "Today a late breaking abstract was presented at the AACR conference with pre-." (4/5/2017)

Who are some of Endocyte's key competitors?

Who are Endocyte's key executives?

Endocyte's management team includes the folowing people:

  • John C. Aplin Ph.D., Independent Chairman of the Board
  • Michael A. Sherman, President, Chief Executive Officer, Director
  • Michael T. Andriole, Chief Financial Officer
  • Philip S. Low Ph.D., Chief Science Officer, Director
  • Michael A. Brinkley, Vice President - Quality
  • Christopher P. Leamon Ph.D., Vice President - Research
  • P. David Mozley M.D., Vice President - Imaging
  • Katherine K. Parker, Vice President of Human Resources
  • Beth A. Taylor, Corporate Controller
  • Cooper Lesley Russell, Director

Who owns Endocyte stock?

Endocyte's stock is owned by a variety of of retail and institutional investors. Top institutional investors include CAMBRIDGE ISOTOPE LABORATORIES, INC. (7.10%). Company insiders that own Endocyte stock include Christopher P Leamon, Fred A Middleton and Philip S Low. View Institutional Ownership Trends for Endocyte.

How do I buy Endocyte stock?

Shares of Endocyte can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endocyte's stock price today?

One share of Endocyte stock can currently be purchased for approximately $5.19.


MarketBeat Community Rating for Endocyte (NASDAQ ECYT)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  193 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  329
MarketBeat's community ratings are surveys of what our community members think about Endocyte and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Endocyte (NASDAQ:ECYT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $7.00 (34.87% upside)
Consensus Price Target History for Endocyte (NASDAQ:ECYT)
Price Target History for Endocyte (NASDAQ:ECYT)
Analysts' Ratings History for Endocyte (NASDAQ:ECYT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/2/2017Cowen and CompanyReiterated RatingHoldHighView Rating Details
10/3/2017WedbushUpgradeNeutral -> Outperform$2.00 -> $7.00HighView Rating Details
11/11/2016Credit Suisse GroupReiterated RatingBuy$7.00N/AView Rating Details
11/4/2015Royal Bank Of CanadaLower Price TargetOutperform$13.00 -> $10.00N/AView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Endocyte (NASDAQ:ECYT)
Earnings by Quarter for Endocyte (NASDAQ:ECYT)
Earnings History by Quarter for Endocyte (NASDAQ ECYT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.25)($0.28)$0.01 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.28)($0.27)$0.01 millionViewN/AView Earnings Details
3/10/2017Q4 2016($0.25)($0.26)$0.01 millionViewN/AView Earnings Details
11/9/2016Q316($0.27)($0.21)$0.03 millionViewListenView Earnings Details
8/4/2016Q2($0.26)($0.25)$0.01 millionViewN/AView Earnings Details
5/4/2016Q116($0.25)($0.24)$0.01 millionViewListenView Earnings Details
3/2/2016Q4($0.27)($0.23)$0.01 millionViewListenView Earnings Details
11/3/2015Q315($0.27)($0.24)$0.03 millionViewN/AView Earnings Details
8/4/2015Q215($0.30)($0.25)$0.01 millionViewN/AView Earnings Details
5/7/2015Q115($0.24)($0.26)$0.01 millionViewN/AView Earnings Details
3/2/2015Q414($0.24)($0.19)$2.55 million$12.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.21)($0.14)$5.10 million$3.90 millionViewN/AView Earnings Details
7/29/2014Q214$0.11$0.52$26.62 million$49.17 millionViewN/AView Earnings Details
5/2/2014Q114($0.15)($0.09)$15.07 million$17.30 millionViewN/AView Earnings Details
2/24/2014Q413($0.14)($0.08)$15.90 million$17.30 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.06)($0.11)$14.24 million$14.50 millionViewN/AView Earnings Details
4/15/2013Q413($0.10)$8.50 million$13.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Endocyte (NASDAQ:ECYT)
2017 EPS Consensus Estimate: ($1.33)
2018 EPS Consensus Estimate: ($0.90)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.32)($0.32)($0.32)
Q2 20171($0.33)($0.33)($0.33)
Q3 20171($0.51)($0.51)($0.51)
Q4 20171($0.17)($0.17)($0.17)
Q1 20181($0.21)($0.21)($0.21)
Q2 20181($0.22)($0.22)($0.22)
Q3 20181($0.23)($0.23)($0.23)
Q4 20181($0.24)($0.24)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Endocyte (NASDAQ:ECYT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Endocyte (NASDAQ:ECYT)
Insider Ownership Percentage: 14.86%
Institutional Ownership Percentage: 28.83%
Insider Trades by Quarter for Endocyte (NASDAQ:ECYT)
Institutional Ownership by Quarter for Endocyte (NASDAQ:ECYT)
Insider Trades by Quarter for Endocyte (NASDAQ:ECYT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/30/2016Christopher P. LeamonVPSell23,244$2.55$59,272.20View SEC Filing  
5/10/2016Philip S LowInsiderBuy11,375$3.52$40,040.00View SEC Filing  
1/19/2016Fred A. MiddletonDirectorBuy10,000$2.79$27,900.00View SEC Filing  
1/15/2016Fred A. MiddletonDirectorBuy20,000$2.80$56,000.00View SEC Filing  
4/9/2014Allen RitterVPSell1,000$21.16$21,160.00View SEC Filing  
3/21/2014Allen RitterVPSell8,000$33.11$264,880.00View SEC Filing  
2/14/2014Philip LowInsiderSell6,000$15.00$90,000.00View SEC Filing  
12/2/2013P Ron EllisCEOSell3,000$12.00$36,000.00View SEC Filing  
9/16/2013Allen RitterVPSell2,000$17.06$34,120.00View SEC Filing  
9/12/2013David MeekInsiderSell10,000$15.50$155,000.00View SEC Filing  
9/3/2013P Ron EllisCEOSell3,000$14.54$43,620.00View SEC Filing  
8/30/2013Allen RitterVPSell6,000$14.36$86,160.00View SEC Filing  
8/6/2013Chandra LovejoyVPSell7,000$17.29$121,030.00View SEC Filing  
8/1/2013P Ron EllisCEOSell3,000$18.12$54,360.00View SEC Filing  
7/15/2013P Ron EllisCEOSell3,000$17.01$51,030.00View SEC Filing  
5/28/2013Ann HanhamDirectorSell9,900$14.10$139,590.00View SEC Filing  
5/22/2013Ann HanhamDirectorSell40,000$14.38$575,200.00View SEC Filing  
5/17/2013Ann HanhamDirectorSell37,200$14.41$536,052.00View SEC Filing  
5/17/2013Binh NguyenVPSell17,300$14.42$249,466.00View SEC Filing  
5/15/2013Ann HanhamDirectorSell40,200$14.69$590,538.00View SEC Filing  
5/14/2013Christopher P LeamonVPSell5,000$14.70$73,500.00View SEC Filing  
2/25/2013Chandra D LovejoyVPSell2,102$9.70$20,389.40View SEC Filing  
12/26/2012Chandra D LovejoyVPSell2,209$9.05$19,991.45View SEC Filing  
11/26/2012Chandra D LovejoyVPSell2,209$8.72$19,262.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Endocyte (NASDAQ:ECYT)
Latest Headlines for Endocyte (NASDAQ:ECYT)
Source:
Loading headlines, please wait.

Social

Chart

Endocyte (ECYT) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.